Key Points
- Ann Varanakis sold 50,000 shares at $6.90 on December 17 for about $345,000, trimming her holding by 13.68% to 315,610 shares (≈$2.18M).
- LifeStance (NASDAQ:LFST) trades near $7.05 with 50/200‑day SMAs of $5.99/$5.37, a market cap of $2.74B, a 12‑month range of $3.74–$8.30, and last quarter reported EPS of $0.02 (beating by $0.03) with revenue up 16.3% year‑over‑year.
- Institutional ownership is ~85.5%, and analysts rate the stock a "Moderate Buy" on average with a $8.83 target, while several large funds (Vanguard, Schwab, Invesco) recently increased positions.
LifeStance Health Group, Inc. (NASDAQ:LFST - Get Free Report) Director Robert Bessler sold 6,442 shares of the company's stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $7.00, for a total transaction of $45,094.00. Following the transaction, the director owned 1,378,954 shares of the company's stock, valued at $9,652,678. This represents a 0.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Robert Bessler also recently made the following trade(s):
- On Monday, December 15th, Robert Bessler sold 12,371 shares of LifeStance Health Group stock. The shares were sold at an average price of $7.00, for a total transaction of $86,597.00.
- On Friday, December 12th, Robert Bessler sold 79,630 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.01, for a total transaction of $558,206.30.
LifeStance Health Group Stock Up 1.6%
LFST opened at $7.05 on Friday. LifeStance Health Group, Inc. has a twelve month low of $3.74 and a twelve month high of $8.30. The company has a quick ratio of 1.58, a current ratio of 1.58 and a debt-to-equity ratio of 0.18. The company has a 50-day moving average price of $5.99 and a 200 day moving average price of $5.37. The company has a market cap of $2.74 billion, a PE ratio of -235.00 and a beta of 1.13.
LifeStance Health Group (NASDAQ:LFST - Get Free Report) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.03. LifeStance Health Group had a negative return on equity of 0.62% and a negative net margin of 0.67%.The company had revenue of $363.81 million for the quarter, compared to analysts' expectations of $355.06 million. During the same period in the previous year, the firm posted ($0.02) EPS. LifeStance Health Group's revenue was up 16.3% compared to the same quarter last year. Sell-side analysts expect that LifeStance Health Group, Inc. will post -0.18 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several brokerages recently commented on LFST. Barclays began coverage on LifeStance Health Group in a research report on Tuesday, December 9th. They set an "overweight" rating and a $8.00 price target for the company. Zacks Research lowered shares of LifeStance Health Group from a "strong-buy" rating to a "hold" rating in a report on Wednesday, November 5th. BTIG Research increased their target price on shares of LifeStance Health Group from $9.00 to $10.00 and gave the company a "buy" rating in a research report on Friday, December 12th. Wall Street Zen downgraded shares of LifeStance Health Group from a "buy" rating to a "hold" rating in a research note on Saturday, October 11th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of LifeStance Health Group in a research report on Monday. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $8.83.
Check Out Our Latest Report on LifeStance Health Group
Institutional Trading of LifeStance Health Group
Large investors have recently added to or reduced their stakes in the stock. AustralianSuper Pty Ltd purchased a new position in shares of LifeStance Health Group during the 3rd quarter worth $17,056,000. Vanguard Group Inc. grew its holdings in shares of LifeStance Health Group by 19.5% in the third quarter. Vanguard Group Inc. now owns 14,613,535 shares of the company's stock valued at $80,374,000 after purchasing an additional 2,383,728 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in LifeStance Health Group by 62.3% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,793,336 shares of the company's stock worth $26,363,000 after purchasing an additional 1,839,465 shares during the last quarter. Dimensional Fund Advisors LP increased its position in LifeStance Health Group by 27.2% during the third quarter. Dimensional Fund Advisors LP now owns 8,363,607 shares of the company's stock worth $45,998,000 after purchasing an additional 1,790,694 shares during the last quarter. Finally, Integral Health Asset Management LLC purchased a new position in LifeStance Health Group during the third quarter worth about $8,250,000. 85.50% of the stock is currently owned by hedge funds and other institutional investors.
About LifeStance Health Group
(
Get Free Report)
LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.
The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
